Efficacy of p120 Antisense-Mediated Therapy for Pancreatic Cancer

Journal of Gastrointestinal Surgery

Volumn 1, Issue 5, 1997, Pages 454-460

  Freeman, James W ^a   Strodel, William E ^a   McGrath, Patrick C ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0141586351     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(97)80133-3     Document Type: Article

References (24)

1. Klempnauer J, Ridder GJ, Bektas H, Pichlmayr R. Surgery for exocrine pancreatic cancer - Who are the 5- and 10-year survivors? Oncology 1995;52:353-359.
2. Hunstad DA, Norton JA. Management of pancreatic carcinoma. Surg Oncol 1995;4:61-74.
3. Kato H, Wakasugi H, Yokoto M, Furkawa M, Makata T, Yamada Y, Funakoshi A. Effectiveness of chemotherapy for advanced adenocarcinoma of the pancreas in combined modality therapy. Int Med 1994;33:142-146.
4. Ruggeri B, Zhang S-Y, Caamano J, DiRado M, Flynn SD, Klein Szango AJP. Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 1992;7:1503-1511.
5. Korc M. Growth factors, receptors, and regulation of normal and malignant pancreas. Int J Pancreat 1995;16:234-236.
6. Mohiuddin M, Ahmed MM, Venkatasubbarao K. c-Ki-ras mutations in peripheral blood of pancreatic cancer patients: A marker for early tumor metastasis. Int J Radiol Oncol Biol Phys 1996;34:161-166.
7. Crooke ST. Therapeutic applications of oligonucleotides. Annu Rev Pharmacol Toxicol 1992;32:329-376.
8. Narayanan R. Antisense therapy of cancer. In Vivo 1994; 8:787-793.
9. Kopper L, Kovalszky I. Antisense tumor therapy (a dream under construction). In Vivo 1994;8:781-786.
10. Wilhelm O, Schmitt M, Hohl S, Senekowitsch R, Graeff H. Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 1995;13:296-302.
11. Yung WK. New approaches in brain tumor therapy using gene transfer and antisense oligonucleotides. Curr Opin Oncol 1994;6:235-239.
12. Johnson TR, Trojan J, Anthony DD, Rudin SD, et al. Gene therapy of rat brain glioblastoma by an episome-based transcriptional cassette expressing antisense IGF-I cDNA. Indian J Biochem Biophys 1994;31:1-13.
13. Fonagy A, Swiderski C, Ostrovsky AM, Bolton WE, Freeman JW. Effect of nucleolar P120 expression level on the proliferation capacity of breast cancer cells. Cancer Res 1994;54: 1859-1864.
14. Freeman JW, McGrath P, Bondada V, Selliah N, Ownby H, Maloney T, Busch RK, Busch H. Prognostic significance of proliferation associated nucleolar antigen P120 in human breast carcinoma. Cancer Res 1991;51:1973-1978.
15. Fonagy A, Swidersky C, Freeman JW. Altered transcription control is responsible for the increased level of proliferation-associated P120 in rapidly growing breast carcinoma. Int J Cancer 1995;60:407-412.
16. Fonagy A, Swiderski C, Freeman JW Nucleolar P120 is expressed as a delayed early response gene and is inducible by DNA damage. J Cell Physiol 1995;64:634-643.
17. Koonin EV Prediction of an rRNA methyltransferase domain in human tumor-specific nucleolar protein P120. Nucleic Acids Res 1994;22:2476-2478.
18. 1- to S-phase transition. Cancer Res 1992;52:5250-5256.
19. Berrozpe G, Schaeffer J, Peinado MA, Real FX, Perucho M. Comparative analysis of mutations in the p53 and k-ras genes in pancreatic cancer. IntJ Cancer 1994;58:185-191.
20. Freeman JW, Mattingly CA, Strodel WE. Increased tumorigenicity in the human pancreatic cell line MIA PaCa-2 is associated with an aberrant regulation of an IGF-1 autocrine loop and lack of expression of the TGF-β type RII receptor. J Cell Phys 1995;165:155-163.
21. Hoke GD, Draper K, Frieier SM, Gonzalez C, Driver VB, Zounes MC, Ecker DJ. Effects of phosphorothioate capping on antisense oligonucleotide stability, hybridization and antiviral efficacy versus herpes simplex infection. Nucl Acid Res 1991;19:5743-5748.
22. Wu SP, Sun LZ, Willson JVK, Humphrey L, Kerbel R, Brattain MG. Repression of autocrine transforming growth factor β1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. Cell Growth Differ 1993;4:115-123.
23. Crooke ST, Bennett CF. Progress in antisense oligonucleotide therapeutics. Annu Rev Pharmacol Toxicol 1996;36:107-129.
24. Shin S. Use of nude mice for tumorigenicity testing and mass propagation. Methods Enzymol 1979;58:370-379.